James Mansfield to Speak at Molecular Imaging Drug Discovery Conference (May 8-10, 2013 in Boston, MA)
2013-01-24 07:53:14 - James Mansfield, Director of Tissue Applications in Life Science and Technology at PerkinElmer, to present “Putting the ‘More’ back in Morphology” at the 6th Imaging in Drug Discovery and Development Conference to be held in Boston, MA on May 8-10, 2013 by GTC.
Biological systems are complex; multiparameter detection methods such as gene/protein expression arrays and flow cytometry make this apparent. However, it is increasingly important not only to measure average expression of molecules, but also their spatial distribution, while preserving cellular and tissue architectural features. Such high-resolution molecular imaging is technically challenging, especially when signals of interest are co-localized. These challenges have
been addressed using multispectral imaging technologies, which enable the simultaneous imaging and quantitation of multiple analytes even in the presence of spatial and spectral overlap. On a microscope, at least 5 can be simultaneously detected and imaged, along with a DAPI counterstain, and sensitivity can be increased by one-to-two orders of magnitude, depending on relative levels of specific label and autofluorescence. Multiple chromogens can be separated in brightfield, which has significance for many pathology-centric studies. Mansfield and his team at PerkinElmer have developed a train-by-example software platform that can be readily trained to separate image regions into appropriate classes (“cancer”, “stroma”, “inflammation”, e.g.) with unprecedented accuracy. By itself this can be very useful, but it can also be combined with specific cellular segmentation and quantitation tools to extract molecular data automatically from appropriate cellular and sub-cellular compartments, information necessary for designing and testing targeted diagnostic and therapeutic reagents.
Delegates will learn about:
• A novel multimarker imaging methodology
• Per-cell intensity quantitation in BF and FL
• Automated image acquisition and analysis of FFPE tissue sections
• Advanced digital and molecular pathology
James Mansfield is a scientist with over 20 years of experience in in-vivo spectroscopy, spectral imaging and applied data analysis, all directed towards finding of novel optical methods for the diagnosis and monitoring of medical conditions. He is currently the Director of Tissue Analysis at PerkinElmer where he is the senior applications scientist for their multispectral imaging and digital pathology systems, which are being used in a wide range of fluorescence and brightfield microscopy applications. Before PerkinElmer, James Mansfield worked at Cambridge Research & Instrumentation, where he helped develop their MSI systems. Prior to that he worked at the National Research Council of Canada as a research scientist and at several small companies developing non-invasive spectroscopic methodologies. His research has included projects ranging from the objective classification of skin cancer spectra using mid-infrared spectral imaging, to developing methods for the non-invasive determination of the severity of rheumatoid arthritis, to the development of the first of several spectral imaging systems able to map out skin oxygenation levels. He holds 6 patents, has numerous pending patent applications and 47 publications in these fields and has served as an invited speaker and session chair and organizer at a variety of international conferences.
GTC’s 6th Imaging in Drug Discovery and Development Conference brings together experts from academia, government, and industry from the National Cancer Institute, Stanford University, City of Hope and the Beckman Research Institute, Yale School of Medicine, Pfizer, Biogen Idec, PerkinElmer, Eisai, Columbia University, Roche, Sanofi-Aventis, Janssen, and many more to discuss the most current developments and applications to further advance their molecular imaging projects on drug discovery and development.
This conference is also part of the Drug Discovery Summit 2013, which consists of this track and three other tracks:
7th Drug Design and Medicinal Chemistry
3rd Epigenetics in Drug Discovery
Orphan Drugs Research and Commercialization
For more information, please visit www.gtcbio.com/index.php?option=com_conference&file=home&cn=5th% ..